Outcomes of patients with melioidosis treated with meropenem

Allen Cheng, D Fisher, Nicholas Anstey, Dianne P Stephens, Susan Jacups, Bart Currie

Research output: Contribution to journalArticlepeer-review


Melioidosis, an infection due to Burkholderia pseudomallei, is endemic in southeast Asia and northern Australia. We reviewed our experience with meropenem in the treatment of severe melioidosis in 63 patients over a 6-year period. Outcomes were similar to those of ceftazidime-treated patients (n = 153) despite a deliberate selection bias to more-unwell patients receiving meropenem. The mortality among meropenem-treated patients was 19%. One patient had a possible drug fever associated with the use of meropenem. We conclude that meropenem (1 g or 25 mg/kg every 8 h intravenously for ?14 days) is an alternative to ceftazidime and imipenem in the treatment of melioidosis. The use of meropenem may be associated with improved outcomes in patients with severe sepsis associated with melioidosis.
Original languageEnglish
Pages (from-to)1763-1765
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Issue number5
Publication statusPublished - 2004


Dive into the research topics of 'Outcomes of patients with melioidosis treated with meropenem'. Together they form a unique fingerprint.

Cite this